Compare BRBS & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | SABS |
|---|---|---|
| Founded | 1893 | 2014 |
| Country | United States | United States |
| Employees | N/A | 86 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.8M | 280.2M |
| IPO Year | 2015 | N/A |
| Metric | BRBS | SABS |
|---|---|---|
| Price | $3.46 | $3.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 363.4K | ★ 730.2K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 24.78% | N/A |
| EPS Growth | ★ 135.48 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $111,284,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $339.00 | ★ N/A |
| Revenue Growth | ★ 123.99 | N/A |
| 52 Week Low | $3.23 | $1.85 |
| 52 Week High | $4.79 | $5.15 |
| Indicator | BRBS | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 41.58 |
| Support Level | $3.41 | $3.42 |
| Resistance Level | $3.53 | $4.10 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 56.25 | 6.36 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.